Condition: Metastatic Esophageal Adenocarcinoma · Advanced Esophageal Adenocarcinoma · Metastatic Gastric Adenocarcinoma · Sponsor: UNICANCER
The goal of this clinical trial is to evaluate the addition of ivonescimab to standard chemotherapy in patients with advanced or metastatic gastric and gastroesophageal adenocarcinoma. The main question it aims to answer is : Does the addition of ivonescimab increase the response to treatment ? Participants will visit the clinic every 2 weeks for checkups, treatment administration and tests for collection of adverse events.
This description comes directly from the study's public registry record.
Nicolas DE SOUSA CARVALHO · 01 71 93 67 09 · n-de-sousa@unicancer.fr
Laure MONARD · 01 73 79 73 09 · l-monard@unicancer.fr
Always discuss trial participation with your own doctor first.
| Centre Léon Bérard | Lyon, France | Recruiting |
| Institut Paoli Calmettes | Marseille, France | Not Yet Recruiting |
| Institut Jean Godinot | Reims, France | Recruiting |
| Institut de Cancerologie de l'Ouest - Site René Gauducheau | Saint-Herblain, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06846346